Seamus O'Brien

Seamus O'Brien

UK
GARDP
R&D Director

Seamus O’Brien joined GARDP as R&D Director in July 2018 and is responsible for strategic development and delivery of the R&D portfolio of treatments for serious drug resistant infections.
Prior to joining as GARDP’s R&D Director, Seamus was responsible for building and leading R&D collaborations and networks to address industry commitment to develop treatment options for antibiotic resistant infections. He played a leading role in establishing novel partnerships for AstraZeneca with the US government’s Biomedical Advanced Research and Development Authority and with the Innovative Medicines Initiative (IMI) New Drugs 4 Bad Bugs programme within Europe as leader of the COMBACTE-CARE consortium addressing carbapenem resistance.
Seamus has extensive experience in pharmaceutical drug development from antibiotic to vaccine clinical development, to leading medical affairs support for a number of product launches.